Our Warfarin Sodium tablets are as effective as Coumadin

The quality of our Warfarin Sodium Tablets, USP is something you can rely on, because it comes from a trusted leader. With more than 100 years of experience in supplying medicinal pharmaceuticals, Mallinckrodt has earned the reputation of an industry expert and the confidence of healthcare providers and patients alike.

In addition to quality pharmaceuticals, Mallinckrodt is dedicated to providing the information you need to prescribe, dispense and use our products safely and effectively. Whether you are a healthcare provider or patient, we hope this website will become, like Mallinckrodt itself, a trusted resource.

Important Safety Information
Warfarin sodium tablets are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism.
WARNING: BLEEDING RISK
Warfarin sodium can cause major or fatal bleeding. Bleeding is more likely to occur during the starting period and with a higher dose (resulting in a higher INR). Risk factors for bleeding include high intensity of anticoagulation (INR >4.0), age ≥65, highly variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, serious heart disease, anemia, malignancy, trauma, renal insufficiency, concomitant drugs (see PRECAUTIONS in full prescribing information), and long duration of warfarin therapy. Regular monitoring of INR should be performed on all treated patients. Those at high risk of bleeding may benefit from more frequent INR monitoring, careful dose adjustment to desired INR, and a shorter duration of therapy. Patients should be instructed about prevention measures to minimize risk of bleeding and to report immediately to physicians signs and symptoms of bleeding (see PRECAUTIONS in full prescribing information).
Anticoagulation is contraindicated in any localized or general physical condition or personal circumstance in which the hazard of hemorrhage might be greater that the potential clinical benefits of anticoagulation, such as: in women who are or may become pregnant, because Warfarin may cause fatal hemorrhage to the fetus and reports of birth malformations; recent or contemplated surgery of the central nervous system, eye or traumatic surgery with large open surfaces; bleeding tendencies associated with active ulceration; threatened abortion, inadequate laboratory facilities; unsupervised patients; spinal puncture.

*Coumadin is a registered trademark of Bristol-Myers Squibb Company.
All trademarks are owned by Mallinckrodt Inc. unless otherwise noted.